STOCK TITAN
  1. Home
  2. News
  3. SWAV

ShockWave Medical Inc - SWAV STOCK NEWS

Welcome to our dedicated news page for ShockWave Medical (Ticker: SWAV), a resource for investors and traders seeking the latest updates and insights on ShockWave Medical.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ShockWave Medical's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ShockWave Medical's position in the market.

News
Shockwave Reducer Demonstrates Consistent, Positive Results in ‘Real-World’ Study
Rhea-AI Summary
Shockwave Medical, Inc. presents positive six-month results from the REDUCER-I trial at the 73rd Annual Scientific Sessions of the American College of Cardiology. The study confirms the effectiveness of Shockwave Reducer in treating refractory angina, showing significant improvements in symptoms and quality of life. The trial also highlights a very favorable safety profile for the device. Results from the COSIRA-II trial are expected to support the regulatory filing for US FDA approval of Shockwave Reducer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.54%
Tags
none
-
News
Johnson & Johnson to Acquire Shockwave Medical
Rhea-AI Summary
Johnson & Johnson (JNJ) to acquire Shockwave Medical, Inc. (SWAV) for $13.1 billion, enhancing its position in cardiovascular intervention. The acquisition aims to drive sales growth, improve patient outcomes, and accelerate operating margin. Shockwave's IVL technology for calcified CAD and PAD treatment aligns with JNJ's focus on cardiovascular disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.07%
Tags
acquisition
-
News
Sonder Capital Appoints Kate Garrett as Managing Partner to Lead Next Generation of Growth
Rhea-AI Summary
Sonder Capital appoints Kate Garrett as Managing Partner, with Co-founders assuming Co-chair roles as the firm closes its second early stage fund, Sonder Futures II. Garrett brings extensive experience and success in healthcare innovation, leading the firm into its next growth phase.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.17%
Tags
partnership management
News
Shockwave Medical to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Rhea-AI Summary
Shockwave Medical, Inc. (SWAV) will participate in the 23rd Annual Needham Virtual Healthcare Conference from April 8 to April 11, 2024. The company's management will have a live fireside chat on April 9, 2024, at 8:45 a.m. Eastern Time.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.04%
Tags
conferences
-
News
Protembis Announces Completion of € 30 Million Series B Financing Round and the Addition of Keith D Dawkins MD to the Board of Directors
Rhea-AI Summary
Protembis GmbH completes a €30 million Series B financing round to support the PROTEMBO Investigational Device Exemption (IDE) Pivotal Trial. The funding was co-led by European VC investors. Dr. Keith D. Dawkins joins the Board of Directors, bringing significant expertise in cardiovascular environments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.04%
Tags
management
-
News
Shockwave Medical Reports Fourth Quarter and Full Year 2023 Financial Results
Rhea-AI Summary
Shockwave Medical, Inc. (SWAV) reported strong financial results for Q4 2023 and full year 2023, with revenue reaching $203.0 million and $730.2 million, respectively. The company achieved a revenue increase of 41% and 49% compared to the same periods in 2022. Shockwave initiated the full U.S. commercial launch of the Shockwave C2+ Coronary Intravascular Lithotripsy (IVL) catheter and obtained new reimbursement for coronary IVL procedures. The company projects revenue growth of 25% to 27% for 2024, aiming to reach $910 million to $930 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.15%
Tags
earnings
News
Shockwave Medical Appoints Renee Gaeta as Chief Financial Officer
Rhea-AI Summary
Shockwave Medical, Inc. (NASDAQ: SWAV) has announced the appointment of Renee Gaeta as the new Chief Financial Officer, effective February 5, 2024. Renee succeeds Dan Puckett, who previously announced his retirement. Renee brings a wealth of experience from the medical device and healthcare industries, having served as CFO at Eko Health and Establishment Labs Holdings, Inc. She is set to play a key role in Shockwave's growth and profitability. Renee expressed her excitement to join Shockwave and contribute to the mission of transforming treatment paradigms for poorly served patient populations with breakthrough technologies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.33%
Tags
management
-
News
Shockwave Medical Provides Quarterly Earnings Release Dates for 2024
Rhea-AI Summary
Shockwave Medical, Inc. (Nasdaq: SWAV) expects to issue quarterly earnings releases and hold conference calls on the following dates: Fourth Quarter 2023 Earnings – Thursday, February 15, 2024 at 4:30 p.m. (ET), First Quarter 2024 Earnings – Monday, May 6, 2024 at 4:30 p.m. (ET), Second Quarter 2024 Earnings – Monday, August 5, 2024 at 4:30 p.m. (ET), Third Quarter 2024 Earnings – Monday, November 4, 2024 at 4:30 p.m. (ET). Investors can listen to the earnings conference call by dialing (877) 704-4453 for domestic callers or (201) 389-0920 for international callers, using conference ID: 13742096. Webcasts of all earnings events will be available at https://ir.shockwavemedical.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.85%
Tags
earnings
-
News
Shockwave Medical to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Shockwave Medical, Inc. (NASDAQ: SWAV) to Participate in 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.98%
Tags
conferences
News
Neptune Medical Appoints Dr. Fred Moll as Chairman of the Board
Rhea-AI Summary
Neptune Medical (Ticker: NPTM) appoints Dr. Fred Moll, a renowned figure in the medical technology industry, as Chairman of the Board. Dr. Moll, known as the father of medical robotics, brings extensive experience from his roles at Sonder Capital, Intuitive Surgical, and Auris Health. His appointment signifies Neptune Medical's commitment to advancing healthcare technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.09%
Tags
management
Stock SWAV logo
ShockWave Medical Inc

Nasdaq:SWAV

SWAV Rankings

#704 Ranked by Market Cap
#3828 Ranked by Stock Gains
N/A Ranked by Dividends

SWAV Stock Data

12.29B
36.82M
1.27%
95.6%
5.43%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Santa Clara

About SWAV

shockwave medical is revolutionizing the interventional treatment of advanced cardiovascular disease by developing technology that targets calcified plaque. inspired by 30-years of safety and efficacy in kidney stone treatment, our lithoplasty® family of catheters delivers localized lithotripsy at the site of cardiovascular calcium that enables gentle balloon dilatation of calcified, stenotic arteries. lithoplasty devices use sonic pressure waves to preferentially impact hard tissue, disrupting calcium, while leaving soft tissue undisturbed. an integrated balloon catheter then dilates the calcified lesion at low-pressure, restoring blood flow. in peripheral vascular clinical study of moderate and severely calcified lesions in 95 patients, lithoplasty technology demonstrated safety and consistent procedure success with low procedural complications. the technology is inherently familiar, easy to use, operates with just the push of a button, and works with existing cardiovascular treatmen